Workshop reportInclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008
Introduction
This first MRC workshop on inclusion body myositis assembled 29 clinicians and scientists. The workshop sought to establish a platform upon which an organised international network of neuromuscular specialists could consider a range of important unresolved issues in relation to IBM. The aims of the workshop were as follows: to review current practice regarding clinical and histopathological diagnostic criteria, to assess recent advances in relation to aetiology and basic science with potential for translation into clinical trials, to review current evidence for IBM treatments and lessons applicable to future trial design, to review genetic advances in IBM and to consider an IBM disease-specific prospective database in an electronic network.
Section snippets
Consideration of clinical diagnostic criteria
After a brief discussion of the typical clinical features of IBM [1], [2], [3], [4], David Hilton-Jones updated the workshop on the current diagnostic criteria for IBM [5], [6], [7], [8]. The widely employed Griggs criteria for ‘definite’ IBM requires fulfilment of several histopathological criteria encompassing degenerative and inflammatory disease processes [5]. According to the Griggs criteria the diagnosis can be considered definite on the basis of fulfilling certain histopathological
Aetiology of IBM
Adrian Miller summarized the evidence underlying the pathogenesis of IBM.
In sIBM, inflammation is manifested by clonally expanded CD8+ T-cells invading fibres expressing MHC Class I. Additional associations with autoimmune-prone haplotypes, paraproteinaemia, and the upregulation of cytokines imply an immunopathogenic component. The coexistence of an IBM-like myopathy with HIV and HTLV-1 infection [10] might imply a viral trigger to autoimmunity in sIBM. Analogous to Alzheimer’s disease, sIBM
Review of evidence for IBM treatments and lessons applicable to future trial design
Michael Rose summarized the existing evidence for IBM treatments. The majority of drug treatments have targeted inflammatory and immune mechanisms. Other trials have included antioxidants and mitochondrial impairment (carnitine and ubiquinone). Nine randomized control trials in IBM have been identified for a Cochrane Systematic Review in press. In addition to being relatively few in number, most have recruited small numbers of patients. Other than those studies coordinated by the north American
Genome-wide studies in IBM
Nick Wood described the options for a genetic approach to complex traits such as sporadic IBM. Whilst associations have been demonstrated between IBM and HLA alleles [31], [32], [33], [34], [35], it remains undetermined whether the predilection of IBM for certain muscle groups or the apparent deficiencies of cytoprotective machinery reflects genetic susceptibility. Possible genetic studies include linkage based or candidate gene studies and more modern techniques such as a genome wide
IBM prospective cohort database
Matt Parton described the full details of the new ‘IBM-net’ database which will represent a structured collection of clinical records and a means to prospectively collect store and retrieve patient data according to agreed protocol. The protocol was presented outlining a range of fields that would be collected. The system is ready to be set up on-line and agreement has been reached with a UK IT provider for this purpose. Potential harmonization with other EU-networks including TREAT-NMD has
List of participants
Mhoriam Ahmed, London, UK Charlotte Brierley, Cambridge, UK Linda Greensmith, London, UK Simon Hammans, Southampton, UK Michael Hanna, London, UK David Hilton-Jones, Oxford, UK Janice Holton, London, UK Henry Houlden, London, UK Russell Lane, London, UK Hanns Lochmuller, Newcastle, UK Adnan Manzur, London, UK Adrian Miller, London, UK James Miller, Newcastle, UK Francesco Muntoni, London, UK Fiona Norwood, London, UK Irene Oakley, Myositis Support Group, UK Richard Orrell, London, UK Matt Parton, London, UK Aleks Radunovic,
Acknowledgement
This IBM workshop was supported by the MRC Centre for Neuromuscular Diseases (Centre Grant G0601943).
References (38)
- et al.
Sporadic inclusion body myositis: a continuing puzzle
Neuromuscul Disord
(2008) - et al.
Polymyositis and dermatomyositis
Lancet
(2003) - et al.
Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model
Neurobiol Aging
(2006) - et al.
A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation
Neuromuscul Disord
(2003) Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis
Curr Opin Neurol
(2004)- et al.
A myopathy with cellular inclusions
Trans Am Neurol Assoc
(1965) Sporadic inclusion body myositis – diagnosis, pathogenesis and therapeutic strategies
Nat Clin Pract Neurol
(2006)- et al.
Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM
Neurology
(2008) - et al.
Inclusion body myositis and myopathies
Ann Neurol
(1995) - et al.
Inclusion body myositis
Curr Opin Rheumatol
(1989)
Inclusion body myositis: clinical and pathological boundaries
Ann Neurol
Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells
Ann Neurol
Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle
Proc Natl Acad Sci USA
Impairment of the ubiquitin–proteasome system by protein aggregation
Science
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle
Proc Natl Acad Sci USA
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle
Brain
Treatment with arimoclomol, a co-inducer of heat shock proteins, delays progression in ALS mice
Nat Med.
Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin
Neurology
Inclusion body myositis: treatment with intravenous immunoglobulin
Neurology
Cited by (91)
Myositis with prominent B cell aggregates may meet classification criteria for sporadic inclusion body myositis
2023, Neuromuscular DisordersSafety and effectiveness of resistance training in patients with late onset Pompe disease - a pilot study
2022, Neuromuscular DisordersMuscle fiber dysfunction contributes to weakness in inclusion body myositis
2019, Neuromuscular DisordersInclusion Body Myositis: Update on Pathogenesis and Treatment
2018, NeurotherapeuticsBotulinum toxin alleviates dysphagia of patients with inclusion body myositis
2017, Journal of the Neurological SciencesCitation Excerpt :IBM diagnosis was always confirmed with a muscle biopsy. The histological biopsy for the diagnosis of IBM was routinely taken from the vastus lateralis muscle (n = 37), and the muscle biopsy findings were compatible with IBM according to the Griggs' or ENMC criteria [26–27]. The histological features for the diagnosis of IBM have been reported earlier [18].